HCW Biologics Inc
Company Profile
Business description
HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.
Contact
2929 N Commerce Parkway
MiramarFL33025
USAT: +1 954 842-2024
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
36
Stocks News & Analysis
stocks
Investment decisions in overvalued bank drive strong results
stocks
Overvalued ASX share hurt by normalising conditions
stocks
After earnings, is Amazon stock a buy, a sell, or fairly valued?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,109.40 | 32.50 | 0.36% |
| CAC 40 | 8,057.46 | 107.28 | 1.35% |
| DAX 40 | 23,999.49 | 429.53 | 1.82% |
| Dow JONES (US) | 46,987.10 | 323.90 | -0.68% |
| FTSE 100 | 9,777.57 | 95.00 | 0.98% |
| HKSE | 26,649.06 | 163.16 | 0.62% |
| NASDAQ | 23,004.54 | 495.26 | -2.11% |
| Nikkei 225 | 50,911.76 | 28.08 | 0.06% |
| NZX 50 Index | 13,617.48 | 40.67 | 0.30% |
| S&P 500 | 6,728.80 | 8.48 | 0.13% |
| S&P/ASX 200 | 8,835.90 | 25.40 | 0.29% |
| SSE Composite Index | 4,018.60 | 21.04 | 0.53% |